JP2007500178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500178A5 JP2007500178A5 JP2006521664A JP2006521664A JP2007500178A5 JP 2007500178 A5 JP2007500178 A5 JP 2007500178A5 JP 2006521664 A JP2006521664 A JP 2006521664A JP 2006521664 A JP2006521664 A JP 2006521664A JP 2007500178 A5 JP2007500178 A5 JP 2007500178A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- formula
- halogen
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 229910052757 nitrogen Inorganic materials 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical class 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- -1 morpholino, piperidinyl Chemical group 0.000 claims 14
- 125000004193 piperazinyl group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 125000002723 alicyclic group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- NGWNEKXXOAOQDH-UHFFFAOYSA-N 3-ethyl-5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-one Chemical compound S1C(=O)N(CC)C(C)=C1C1=CC=NC(NC=2C=NC(OC)=CC=2)=N1 NGWNEKXXOAOQDH-UHFFFAOYSA-N 0.000 claims 2
- QAJUHIMNXXLTMC-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(1-methylpyridin-1-ium-3-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=[N+](C)C=CC=2)=N1 QAJUHIMNXXLTMC-UHFFFAOYSA-N 0.000 claims 2
- GDTPAFZBQRZJLZ-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(6-methoxypyridin-3-yl)pyrimidin-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 GDTPAFZBQRZJLZ-UHFFFAOYSA-N 0.000 claims 2
- WLHYKSRGEAQKRU-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(6-pyrrolidin-1-ylpyridin-3-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=NC(=CC=2)N2CCCC2)=N1 WLHYKSRGEAQKRU-UHFFFAOYSA-N 0.000 claims 2
- CWEXJIJARQBDRX-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-pyridin-2-ylpyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2N=CC=CC=2)=N1 CWEXJIJARQBDRX-UHFFFAOYSA-N 0.000 claims 2
- IKSUOSUXSHNWGN-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-pyridin-3-ylpyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=NC=CC=2)=N1 IKSUOSUXSHNWGN-UHFFFAOYSA-N 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- GTYGNPKTSFCTCV-UHFFFAOYSA-N 5-[2-[(6-chloropyridin-3-yl)amino]pyrimidin-4-yl]-3,4-dimethyl-1,3-thiazol-2-one Chemical compound S1C(=O)N(C)C(C)=C1C1=CC=NC(NC=2C=NC(Cl)=CC=2)=N1 GTYGNPKTSFCTCV-UHFFFAOYSA-N 0.000 claims 2
- LGYQJDCKJGGWOZ-UHFFFAOYSA-N 5-[2-[(6-chloropyridin-3-yl)amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=NC(Cl)=CC=3)N=CC=2)=C1C LGYQJDCKJGGWOZ-UHFFFAOYSA-N 0.000 claims 2
- JLOLJJBFULWRJY-UHFFFAOYSA-N 5-[2-[(6-chloropyridin-3-yl)amino]pyrimidin-4-yl]-n,4-dimethyl-1,3-thiazol-2-amine Chemical compound S1C(NC)=NC(C)=C1C1=CC=NC(NC=2C=NC(Cl)=CC=2)=N1 JLOLJJBFULWRJY-UHFFFAOYSA-N 0.000 claims 2
- KUFLTQZFYSQEBD-UHFFFAOYSA-N 5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C2=C(N=C(N)S2)C)=N1 KUFLTQZFYSQEBD-UHFFFAOYSA-N 0.000 claims 2
- MYRUMSKRURNVCK-UHFFFAOYSA-N 5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-n,4-dimethyl-1,3-thiazol-2-amine Chemical compound S1C(NC)=NC(C)=C1C1=CC=NC(NC=2C=NC(OC)=CC=2)=N1 MYRUMSKRURNVCK-UHFFFAOYSA-N 0.000 claims 2
- KIQBQOCBYDOQGR-UHFFFAOYSA-N 5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-n,n,4-trimethyl-1,3-thiazol-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C2=C(N=C(S2)N(C)C)C)=N1 KIQBQOCBYDOQGR-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 108090000433 Aurora kinases Proteins 0.000 claims 2
- 102000003989 Aurora kinases Human genes 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 102000038624 GSKs Human genes 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005594 diketone group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- VWBLMCLNBXDOQL-UHFFFAOYSA-N n,4-dimethyl-5-[2-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound S1C(NC)=NC(C)=C1C1=CC=NC(NC=2C=NC(=CC=2)N2CCN(C)CC2)=N1 VWBLMCLNBXDOQL-UHFFFAOYSA-N 0.000 claims 2
- VFJKOISNXCSLRD-UHFFFAOYSA-N n-(2-methoxyethyl)-5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound S1C(NCCOC)=NC(C)=C1C1=CC=NC(NC=2C=NC(OC)=CC=2)=N1 VFJKOISNXCSLRD-UHFFFAOYSA-N 0.000 claims 2
- MMTRPGUYGOMIEQ-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=NC(Cl)=CC=2)=N1 MMTRPGUYGOMIEQ-UHFFFAOYSA-N 0.000 claims 2
- UEQKAPPKPMTDDR-UHFFFAOYSA-N n-ethyl-5-[2-[(6-methoxypyridin-3-yl)amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound S1C(NCC)=NC(C)=C1C1=CC=NC(NC=2C=NC(OC)=CC=2)=N1 UEQKAPPKPMTDDR-UHFFFAOYSA-N 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 102000001267 GSK3 Human genes 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- POYKYDQRRQKNPH-UHFFFAOYSA-N n-(6-methoxypyridin-3-yl)-4-(4-methyl-2-morpholin-4-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C2=C(N=C(S2)N2CCOCC2)C)=N1 POYKYDQRRQKNPH-UHFFFAOYSA-N 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0317842A GB0317842D0 (en) | 2003-07-30 | 2003-07-30 | Compound |
| GB0318347A GB0318347D0 (en) | 2003-08-05 | 2003-08-05 | Compound |
| PCT/GB2004/003282 WO2005012298A1 (en) | 2003-07-30 | 2004-07-30 | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500178A JP2007500178A (ja) | 2007-01-11 |
| JP2007500178A5 true JP2007500178A5 (https=) | 2007-09-13 |
Family
ID=34117650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521664A Pending JP2007500178A (ja) | 2003-07-30 | 2004-07-30 | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060241297A1 (https=) |
| EP (1) | EP1648887A1 (https=) |
| JP (1) | JP2007500178A (https=) |
| AU (1) | AU2004261482A1 (https=) |
| BR (1) | BRPI0412351A (https=) |
| CA (1) | CA2533870A1 (https=) |
| IL (1) | IL173380A0 (https=) |
| WO (1) | WO2005012298A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20080194561A1 (en) * | 2005-07-26 | 2008-08-14 | Jerry Leroy Adams | Compounds |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| DE102005048072A1 (de) * | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
| UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
| US20080214560A1 (en) * | 2005-10-03 | 2008-09-04 | Astrazeneca Ab | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| EP1951307A2 (en) * | 2005-11-11 | 2008-08-06 | Cyclacel Limited | Combination of a cdk-inhibitor and a hdac-inhibitor |
| DE102006001161A1 (de) * | 2006-01-06 | 2007-07-12 | Qiagen Gmbh | Verfahren zum Nachweis von Cytosin-Methylierungen |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
| WO2009076140A1 (en) * | 2007-12-13 | 2009-06-18 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| HUE030912T2 (en) | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2010117787A2 (en) * | 2009-03-30 | 2010-10-14 | The Brigham And Women's Hospital, Inc. | Inhibiting eph b-3 kinase |
| US20120077813A1 (en) | 2009-04-15 | 2012-03-29 | Astrazeneca Ab | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease |
| EP2545037A1 (en) | 2010-03-10 | 2013-01-16 | Ingenium Pharmaceuticals GmbH | Inhibitors of protein kinases |
| ES2577829T3 (es) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| USRE49850E1 (en) * | 2015-08-04 | 2024-02-27 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN108794458A (zh) * | 2018-07-31 | 2018-11-13 | 湖北欣瑞康医药科技有限公司 | 一种芳基取代嘧啶胺酰基化衍生物的制备方法 |
| EP4452248A4 (en) | 2021-12-20 | 2025-12-10 | Nimml Inst | IMMUNOREGULATORY COMPOUNDS |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7922900A (en) * | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
| AU3704101A (en) * | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| CN100355751C (zh) * | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
-
2004
- 2004-07-30 JP JP2006521664A patent/JP2007500178A/ja active Pending
- 2004-07-30 WO PCT/GB2004/003282 patent/WO2005012298A1/en not_active Ceased
- 2004-07-30 AU AU2004261482A patent/AU2004261482A1/en not_active Abandoned
- 2004-07-30 CA CA002533870A patent/CA2533870A1/en not_active Abandoned
- 2004-07-30 BR BRPI0412351-4A patent/BRPI0412351A/pt not_active IP Right Cessation
- 2004-07-30 EP EP04743608A patent/EP1648887A1/en not_active Withdrawn
-
2006
- 2006-01-25 US US11/339,059 patent/US20060241297A1/en not_active Abandoned
- 2006-01-26 IL IL173380A patent/IL173380A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500178A5 (https=) | ||
| Nammalwar et al. | Recent advances in pyrimidine-based drugs | |
| JP2007509117A5 (https=) | ||
| JP2007520540A5 (https=) | ||
| EP3444246B1 (en) | 2,4-disubstituted pyrimidine derivative as cdk inhibitor and use thereof | |
| JP2010523534A5 (https=) | ||
| JP2008526824A5 (https=) | ||
| US9284298B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| US10342796B2 (en) | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | |
| JP4478016B2 (ja) | フェニル−［４−（３−フェニル−１ｈ−ピラゾール−４−イル）−ピリミジン−２−イル］−アミン誘導体 | |
| KR101036394B1 (ko) | 단백질 키나아제 의존성 질환 치료에 유용한 디아릴우레아 유도체 | |
| JP2022516882A (ja) | Ｍａｔ２ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 | |
| JP2023507669A (ja) | ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物 | |
| JP2017125037A (ja) | イミダゾピロリジノン化合物 | |
| EP1648887A1 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| CA2531619A1 (en) | Biaryl piperazinyl-pyridine analogues | |
| JP2021523177A5 (https=) | ||
| CN105408334A (zh) | 作为激酶抑制剂的取代的吡唑并嘧啶类化合物 | |
| Romanelli et al. | Synthetic approaches to piperazine-containing drugs approved by FDA in the period of 2011–2023 | |
| RU2009140753A (ru) | Соединения | |
| HK1217324A1 (zh) | 二氨基杂芳基取代的吲唑 | |
| JP7583838B2 (ja) | ピリミジン誘導体及びその製造方法並びにその使用 | |
| KR20150015501A (ko) | 방향족 복소환 유도체 및 의약 | |
| Li et al. | Discovery of hexahydrofuro [3, 2-b] furans as new kinase-selective and orally bioavailable JAK3 inhibitors for the treatment of leukemia harboring a JAK3 activating mutant | |
| Song et al. | Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023) |